



Addressing the COVID-19 Crisis: An Open Forum Webinar Series for Pharmacy

COVID-19 and Other Immunizations: A Review of Recent Updates
February 24, 2022

For Every Pharmacist. For All of Pharmacy.

[pharmacist.com](https://www.pharmacist.com)



Sandra Leal, PharmD, MPH, FAPhA, CDCES
President
American Pharmacists Association

Host and Moderator

This webinar is supported by Grant Number, 6 NH23IP922572-01-01, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

Today's Webinar

Review recent updates to recommendations for COVID-19 vaccines and other adult vaccines.



Stephan Foster, PharmD, FAPhA

Former APhA Liaison to ACIP
CAPT (Ret.), U.S.P.H.S.

Guest Speaker



Mitch Rothholz, RPh, MBA

Chief of Governance & State Affiliates
American Pharmacists Association

Executive Director
American Pharmacists Association Foundation

Speaker



Dan Zlott, PharmD, BCOP

Senior Vice President

Education & Business Development

American Pharmacists Association

Subject Matter Expert: Q&A



Ilisa G. Bernstein, PharmD, JD, FAPhA

Senior Vice President

Pharmacy Practice & Government Affairs

American Pharmacists Association

Subject Matter Expert: Q&A

Format for Today's Webinar

1:00pm: Introductions

1:05pm: Discussion with Steve Foster & Mitch Rothholz

1:30pm: Open Forum Discussion: Share Your Questions & Thoughts

1:50pm: Review of APhA's Ongoing Activities & What's Coming

Open Forum Ground Rules

- Use the **Questions** field on the GoToWebinar toolbar to submit comments and questions related to the topic discussion.
- We will try to get to as many comments and questions as possible!
- Refer to the **Handout** in the GoToWebinar toolbar to access today's slides and links to resources.
- This webinar recording will be made available.

Discussion with Steve Foster & Mitch Rothholz

Review recent updates to recommendations for COVID-19 vaccines and other adult vaccines.

Updated Immunization Schedules Released

Recommended Adult Immunization Schedule for ages 19 years or older

UNITED STATES
2022

How to use the adult immunization schedule

- 1 Determine recommended vaccinations by age (Table 1)
- 2 Assess need for additional recommended vaccinations by medical condition or other indication (Table 2)
- 3 Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- 4 Review contraindications and precautions for vaccine types (Appendix)

Vaccines in the Adult Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
<i>Haemophilus influenzae</i> type b vaccine	Hib	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	HepA	Havrix® Vaqta®
Hepatitis A and hepatitis B vaccine	HepA-HepB	Twinrix®
Hepatitis B vaccine	HepB	Engerix-B® Recombivax HB® Heplisav-B®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)	IV4	Many brands
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Influenza vaccine (recombinant)	RIV4	Flublok® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D MenACWY-CRM MenACWY-TT	Menactra® Menveo® MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero® Trumenba®
Pneumococcal 15-valent conjugate vaccine	PCV15	Vaxneuvance™
Pneumococcal 20-valent conjugate vaccine	PCV20	Prevnar 20™
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax 23®
Tetanus and diphtheria toxoids	Td	Tenivac® Tdvax™
Tetanus and diphtheria toxoids and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Varicella vaccine	VAR	Varivax®
Zoster vaccine, recombinant	RZV	Shingrix

*Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American College of Physicians (www.acponline.org), American College of Obstetrics and Gynecology (www.acog.org), American Academy of Family Physicians (www.aafp.org), American Academy of Nurse-Midwives (www.midwife.org), American Academy of Physician Assistants (www.aapa.org), and National Association of Pediatric Nurse Practitioners (www.napnap.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant post-vaccination adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

Injury claims

All vaccines included in 23-valent polysaccharide Vaccine Injury Compensation claim is available at www.hhs.gov/oig/ovd

Questions or comments

Contact www.cdc.gov/cdc-800-232-4636, in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays

Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/sun-manual
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html



Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger

UNITED STATES
2022

Vaccines in the Child and Adolescent Immunization Schedule*

Vaccine	Abbreviation(s)	Trade name(s)
Dengue vaccine	DEN4CYD	Dengvaxia®
Diphtheria, tetanus, and acellular pertussis vaccine	DTaP	Daptacel® Infanrix®
Diphtheria, tetanus vaccine	DT	No trade name
<i>Haemophilus influenzae</i> type b vaccine	Hib (PRP-T) Hib (PRP-OMP)	ActHIB® Hiberix® PedvaxHIB®
Hepatitis A vaccine	HepA	Havrix® Vaqta®
Hepatitis B vaccine	HepB	Engerix-B® Recombivax HB®
Human papillomavirus vaccine	HPV	Gardasil 9®
Influenza vaccine (inactivated)	IV4	Multiple
Influenza vaccine (live, attenuated)	LAIV4	FluMist® Quadrivalent
Measles, mumps, and rubella vaccine	MMR	M-M-R II®
Meningococcal serogroups A, C, W, Y vaccine	MenACWY-D MenACWY-CRM MenACWY-TT	Menactra® Menveo® MenQuadfi®
Meningococcal serogroup B vaccine	MenB-4C MenB-FHbp	Bexsero® Trumenba®
Pneumococcal 13-valent conjugate vaccine	PCV13	Prevnar 13®
Pneumococcal 23-valent polysaccharide vaccine	PPSV23	Pneumovax 23®
Poliovirus vaccine (inactivated)	IPV	IPOL®
Rotavirus vaccine	RV1 RV5	Rotarix® RotaTeq®
Tetanus, diphtheria, and acellular pertussis vaccine	Tdap	Adacel® Boostrix®
Tetanus and diphtheria vaccine	Td	Tenivac® Tdvax™
Varicella vaccine	VAR	Varivax®

Combination vaccines (use combination vaccines instead of separate injections when appropriate)

DTaP, hepatitis B, and inactivated poliovirus vaccine	DTaP-HepB-IPV	Pediarix®
DTaP, inactivated poliovirus, and <i>Haemophilus influenzae</i> type b vaccine	DTaP-IPV/Hib	Pentacel®
DTaP and inactivated poliovirus vaccine	DTaP-IPV	Kinrix® Quadacel®
DTaP, inactivated poliovirus, <i>Haemophilus influenzae</i> type b, and hepatitis B vaccine	DTaP-IPV-Hib-HepB	Vaxelis®
Measles, mumps, rubella, and varicella vaccine	MMRV	ProQuad®

*Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series if there are extended intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is for identification purposes only and does not imply endorsement by the ACIP or CDC.

How to use the child and adolescent immunization schedule

- 1 Determine recommended vaccine by age (Table 1)
- 2 Determine recommended interval for catch-up vaccination (Table 2)
- 3 Assess need for additional recommended vaccines by medical condition or other indication (Table 3)
- 4 Review vaccine types, frequencies, intervals, and considerations for special situations (Notes)
- 5 Review contraindications and precautions for vaccine types (Appendix)

Recommended by the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Control and Prevention (www.cdc.gov), American Academy of Pediatrics (www.aap.org), American Academy of Family Physicians (www.aafp.org), American College of Obstetrics and Gynecologists (www.acog.org), American College of Nurse-Midwives (www.midwife.org), American Academy of Physician Assistants (www.aapa.org), and National Association of Pediatric Nurse Practitioners (www.napnap.org).

Report

- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or 800-822-7967

Questions or comments

Contact www.cdc.gov/cdc-800-232-4636, in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays

Download the CDC Vaccine Schedules app for providers at www.cdc.gov/vaccines/schedules/hcp/schedule-app.html

Helpful information

- Complete Advisory Committee on Immunization Practices (ACIP) recommendations: www.cdc.gov/vaccines/hcp/acip-recs/index.html
- General Best Practice Guidelines for Immunization (including contraindications and precautions): www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
- Vaccine information statements: www.cdc.gov/vaccines/hcp/vis/index.html
- Manual for the Surveillance of Vaccine-Preventable Diseases (including case identification and outbreak response): www.cdc.gov/vaccines/pubs/sun-manual
- ACIP Shared Clinical Decision-Making Recommendations: www.cdc.gov/vaccines/acip/acip-scdm-faqs.html



U.S. Department of Health and Human Services
Centers for Disease Control and Prevention


Scan QR code for access to online schedule




CS110020-A

MMWR - February 18, 2022
Adult Immunization Schedule
Child & Adolescent Immunization Schedule

Daily Trends in Number of COVID-19 Cases in The United States Reported to CDC



Age-specific COVID-19 vaccine recommendations for moderate and severely immunocompromised individuals



Updated COVID-19 Vaccine Timing for Certain Individuals

Primary series vaccine manufacturer	Age group	Number of doses in primary series	Number of booster doses	Interval between 1 st and 2 nd dose *	Interval between primary series and booster dose
Pfizer-BioNTech	5–11 years	2	NA	3 weeks	N/A
Pfizer-BioNTech	≥12 years	2	1	3-8 weeks**	≥5 months
Moderna	≥18 years	2	1	4-8 weeks**	≥5 months
Janssen	≥18 years	1	1	NA	≥2 months

*For the vaccination schedule for people who are moderately or severely immunocompromised, see [Table 3](#).


An **8-week interval may be optimal for people ages 12 years through 64 years, and especially for males ages 12 through 39 years, who are not moderately or severely immunocompromised. A **shorter interval** (3 weeks for Pfizer-BioNTech; 4 weeks for Moderna) between the first and second dose remains the recommended interval for: people who are moderately or severely immunocompromised; adults ages 65 years and older; and others who need early protection due to increased concern about community transmission or risk of severe disease.

Today's Webinar

Review recent updates to recommendations for COVID-19 vaccines and other adult vaccines.

Open Forum Discussion: Share Your Questions & Thoughts

Review of APhA's Ongoing Activities & What's Coming



New design!

<https://pharmacist.com/Practice/COVID-19/COVID-19-Vaccines>



Current Guidance & Recommendations



**mRNA Vaccines
(Pfizer & Moderna)**



**Viral Vector Vaccines
(Janssen)**



**Protein-Based Vaccines
(Novavax)**



Adolescents & Children



**Immunocompromised
Individuals**




Documentation & Billing



Storage & Administration



Authority



**Implementation
Strategies**



Vaccine Confidence



A_{Ph}A2022

Registration is Open

[Schedule](#)[Search](#)[Login](#)

SCAN ME

REGISTER

[Registration](#)[Schedule of Events](#)[Exhibitor Information](#)[Schedule at a Glance](#)[Speakers](#)[General Information](#)[Hotel and Travel](#)

ICON LEGEND



This session is not in your schedule.



This session is in your schedule. Click again to remove it.



IMPORTANT UPDATE: Vaccination and Mask Requirements.
[Click to view General Information Page.](#)



We Are Stronger Together

**Register by February 17
to save up to \$200!**





Join Us!

Thursday, March 10th 1:00-2:00 pm ET

[Register Here](#)

Today's webinar will be available soon

<https://pharmacist.com/Practice/COVID-19/Open-Forum-Webinars>